Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.28965
-0.0121 (-4.03%)
Oct 30, 2026, 12:33 PM EDT - Market open
Mereo BioPharma Group Revenue
In the year 2025, Mereo BioPharma Group had annual revenue of $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
46.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 500.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Werewolf Therapeutics | 21.00M |
| Caribou Biosciences | 10.04M |
| Apollomics | 8.84M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
| iBio, Inc. | 100.00K |
MREO News
- 2 months ago - JPMorgan downgrades Mereo to Underweight on regulatory uncertainty - TheFly
- 2 months ago - Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan - TheFly
- 2 months ago - Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 - Nasdaq
- 2 months ago - Mereo BioPharma Group Releases Q2 2026 Financial Results - AlphaStreet
- 2 months ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq
- 2 months ago - Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 2 months ago - Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) - PRNewsWire
- 5 months ago - 4basebio Announces Appointment of Chief Financial Officer and Board Changes - GlobeNewsWire